Remicade Biosimilar Global Market Report 2025

Description

A Remicade biosimilar is a biological drug that is similar to Remicade, and it is utilized in the treatment of certain autoimmune diseases in both adults and children. This type of medication is specifically designed to address autoimmune inflammatory conditions such as psoriasis, rheumatoid arthritis, Crohn's disease, and ulcerative colitis.

The main types of biosimilars in the Remicade biosimilars category come in strengths of 100 mg/10 ml and 500 mg/50 ml. The 100 mg/10 ml strength indicates the amount of drug in the dosage form or a unit of the dosage form, equivalent to 100 mg per 10 ml. The applications for these biosimilars include the treatment of conditions such as ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriatic arthritis, and plaque psoriasis. Additionally, they are used for various applications in the treatment of blood disorders and oncology diseases.

The remicade biosimilars market research report is one of a series of new reports from The Business Research Company that provides remicade biosimilars market statistics, including remicade biosimilars industry global market size, regional shares, competitors with a remicade biosimilars market share, detailed remicade biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the remicade biosimilars industry. This remicade biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade biosimilar market size has grown exponentially in recent years. It will grow from $3.95 billion in 2024 to $4.93 billion in 2025 at a compound annual growth rate (CAGR) of 24.9%. The growth in the historic period can be attributed to the introduction of remicade (infliximab), biotechnology advancements, biologics patent expiry, regulatory pathway establishment, and healthcare cost pressures

The remicade biosimilar market size is expected to see exponential growth in the next few years. It will grow to $11.07 billion in 2029 at a compound annual growth rate (CAGR) of 22.4%. The growth in the forecast period can be attributed to patent expirations, rising demand for cost-effective therapies, biosimilar pipeline development, reimbursement policies, market consolidation. Major trends in the forecast period include physician prescribing behavior, biosimilar lifecycle management, biosimilar naming conventions, biosimilar interchangeability, biosimilar real-world evidence.

The increasing incidence of autoimmune diseases is anticipated to drive the growth of the remicade biosimilar market in the future. Autoimmune diseases are conditions where the immune system erroneously attacks and damages the body's tissues and organs. Remicade biosimilars are utilized in treating autoimmune diseases by offering an effective therapeutic option to manage symptoms and reduce inflammation. For example, in July 2023, data from Public Health Scotland, a national organization in Scotland, indicated that in 2022, the number of newly diagnosed patients with multiple sclerosis (MS) rose to 87.2%, up from 85.7% in 2020, with 491 new cases reported, resulting in a total of 6,359 cases in 2022. Thus, the increasing incidence of autoimmune diseases is propelling the growth of the remicade biosimilar market.

The growing healthcare expenditure is significantly impacting the growth of the remicade biosimilar market in the coming years. Healthcare expenditure refers to the total amount spent on healthcare goods and services within a specific timeframe, typically on an annual basis. Biologic drugs, such as Remicade, are often costly. As healthcare spending increases, there is a heightened focus on cost containment and the more efficient allocation of resources. Biosimilars provide a more economical alternative to their originator biologics, including Remicade. For instance, in October 2024, the Centers for Medicare & Medicaid Services, a U.S.-based federal agency, reported that prescription drug spending grew by 8.4%, reaching $405.9 billion in 2022, surpassing the 6.8% growth recorded in 2021. Therefore, the rising healthcare expenditure is expected to drive the remicade biosimilar market.

Innovation in product development is a notable trend in the Remicade biosimilar market, with major companies focusing on introducing innovative products to maintain their market position. An example is Amgen Inc., a US-based biotechnology company, which launched Amjevita in January 2023. Amjevita is a biosimilar version of AbbVie's Humira, designed to be as safe and effective as the original drug. With a lower cost than Humira, Amjevita offers patients a more affordable treatment option for autoimmune diseases such as rheumatoid arthritis and Crohn's disease.

Major companies in the remicade biosimilar market are concentrating on creating innovative solutions, such as subcutaneous formulations, to achieve a competitive edge. Subcutaneous formulations of Remicade offer an alternative method of administration for treating autoimmune diseases, enabling self-administration and potentially enhancing patient adherence to therapy. For example, in March 2024, Celltrion, a biopharmaceutical company based in South Korea, introduced Zymfentra, a biosimilar to Remicade (infliximab), priced at $6,181.08 for two doses over four weeks. This formulation received FDA approval as the first subcutaneous infliximab option for maintaining therapy in adults with moderate-to-severe ulcerative colitis and Crohn's disease. Eligible patients with commercial insurance can access copay assistance of $5 per month, while uninsured or underinsured individuals may receive Zymfentra at no cost.

In April 2022, Samsung Biologics, a South Korea-based biotechnology company, acquired Samsung Bioepis Co. Ltd. for $2.3 billion. This acquisition positions Samsung Biologics to meet the increasing demand for biosimilars, access a broader range of products, expand manufacturing capacity, and strengthen its global reach. Samsung Bioepis Co. Ltd. is a South Korea-based biopharmaceutical company specializing in producing Remicade biosimilar products.

Major companies operating in the remicade biosimilar market include Novartis AG, Amgen Inc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Merck And Co. Inc., LG Chem Ltd., Nippon Kayaku Co. Ltd., Celltrion Inc., Nichi-iko Pharmaceutical Co. Ltd., Biocon Limited, Alvotech S.A., MabPharm Ltd., Genor Biopharma Co. Ltd, Shanghai Biomabs Pharmaceuticals Co. Ltd., Samsung Bioepis Co. Ltd., Biocad Biopharmaceutical Co, EPIRUS Biopharmaceuticals Inc., Ranbaxy Laboratories Limited, BioXpress Therapeutics SA, Mabion S.A

Europe was the largest region in the remicade biosimilar market in 2024. The regions covered in the remicade biosimilar market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the remicade biosimilar market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The remicade biosimilar market consists of sales of inflectra, renflexis, avolsa, remsima, infimab, and avolsa. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Remicade Biosimilar Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on remicade biosimilar market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for remicade biosimilar ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The remicade biosimilar market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: 100mg/10ml; 500mg/50ml
2) By Disease Indication: Ulcerative Colitis; Rheumatoid Arthritis; Ankylosing Spondylitis; Crohn's Disease; Psoriatic Arthritis; Plaque Psoriasis
3) By Application: Blood Disorders; Oncology Diseases
Subsegments:
1) By 100 Mg/10 Ml: Vials For Injection; Prefilled Syringes
2) By 500 Mg/50 Ml: Vials For Injection; Prefilled Syringes
Companies Mentioned: Novartis AG; Amgen Inc; Viatris Inc.; Teva Pharmaceutical Industries Ltd.; Biogen Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25260

1. Executive Summary

2. Remicade Biosimilar Market Characteristics

3. Remicade Biosimilar Market Trends And Strategies

4. Remicade Biosimilar Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Remicade Biosimilar Growth Analysis And Strategic Analysis Framework

5.1. Global Remicade Biosimilar PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Remicade Biosimilar Market Growth Rate Analysis
5.4. Global Remicade Biosimilar Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Remicade Biosimilar Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Remicade Biosimilar Total Addressable Market (TAM)

6. Remicade Biosimilar Market Segmentation

6.1. Global Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
100mg/10ml
500mg/50ml
6.2. Global Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Crohn's Disease
Psoriatic Arthritis
Plaque Psoriasis
6.3. Global Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Blood Disorders
Oncology Diseases
6.4. Global Remicade Biosimilar Market, Sub-Segmentation Of 100 Mg/10 Ml, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vials For Injection
Prefilled Syringes
6.5. Global Remicade Biosimilar Market, Sub-Segmentation Of 500 Mg/50 Ml, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vials For Injection
Prefilled Syringes

7. Remicade Biosimilar Market Regional And Country Analysis

7.1. Global Remicade Biosimilar Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Remicade Biosimilar Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Remicade Biosimilar Market

8.1. Asia-Pacific Remicade Biosimilar Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Remicade Biosimilar Market

9.1. China Remicade Biosimilar Market Overview
9.2. China Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Remicade Biosimilar Market

10.1. India Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Remicade Biosimilar Market

11.1. Japan Remicade Biosimilar Market Overview
11.2. Japan Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Remicade Biosimilar Market

12.1. Australia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Remicade Biosimilar Market

13.1. Indonesia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Remicade Biosimilar Market

14.1. South Korea Remicade Biosimilar Market Overview
14.2. South Korea Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Remicade Biosimilar Market

15.1. Western Europe Remicade Biosimilar Market Overview
15.2. Western Europe Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Remicade Biosimilar Market

16.1. UK Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Remicade Biosimilar Market

17.1. Germany Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Remicade Biosimilar Market

18.1. France Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Remicade Biosimilar Market

19.1. Italy Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Remicade Biosimilar Market

20.1. Spain Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Remicade Biosimilar Market

21.1. Eastern Europe Remicade Biosimilar Market Overview
21.2. Eastern Europe Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Remicade Biosimilar Market

22.1. Russia Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Remicade Biosimilar Market

23.1. North America Remicade Biosimilar Market Overview
23.2. North America Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Remicade Biosimilar Market

24.1. USA Remicade Biosimilar Market Overview
24.2. USA Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Remicade Biosimilar Market

25.1. Canada Remicade Biosimilar Market Overview
25.2. Canada Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Remicade Biosimilar Market

26.1. South America Remicade Biosimilar Market Overview
26.2. South America Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Remicade Biosimilar Market

27.1. Brazil Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Remicade Biosimilar Market

28.1. Middle East Remicade Biosimilar Market Overview
28.2. Middle East Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Remicade Biosimilar Market

29.1. Africa Remicade Biosimilar Market Overview
29.2. Africa Remicade Biosimilar Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Remicade Biosimilar Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Remicade Biosimilar Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Remicade Biosimilar Market Competitive Landscape And Company Profiles

30.1. Remicade Biosimilar Market Competitive Landscape
30.2. Remicade Biosimilar Market Company Profiles
- 30.2.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Amgen Inc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Biogen Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Remicade Biosimilar Market Other Major And Innovative Companies

31.1. Merck And Co. Inc.
31.2. LG Chem Ltd.
31.3. Nippon Kayaku Co. Ltd.
31.4. Celltrion Inc.
31.5. Nichi-iko Pharmaceutical Co. Ltd.
31.6. Biocon Limited
31.7. Alvotech S.A.
31.8. MabPharm Ltd.
31.9. Genor Biopharma Co. Ltd
31.10. Shanghai Biomabs Pharmaceuticals Co. Ltd.
31.11. Samsung Bioepis Co. Ltd.
31.12. Biocad Biopharmaceutical Co
31.13. EPIRUS Biopharmaceuticals Inc.
31.14. Ranbaxy Laboratories Limited
31.15. BioXpress Therapeutics SA

32. Global Remicade Biosimilar Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Remicade Biosimilar Market

34. Recent Developments In The Remicade Biosimilar Market

35. Remicade Biosimilar Market High Potential Countries, Segments and Strategies

35.1 Remicade Biosimilar Market In 2029 - Countries Offering Most New Opportunities
35.2 Remicade Biosimilar Market In 2029 - Segments Offering Most New Opportunities
35.3 Remicade Biosimilar Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer